featured
Overall Survival in Patients With HR+/HER2− Metastatic Breast Cancer Receiving CDK4/6 Inhibitors in Addition to Endocrine Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study
Cancer 2023 Feb 09;[EPub Ahead of Print], RK Goyal, H Chen, SM Abughosh, HM Holmes, SD Candrilli, ML JohnsonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.